News Features Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate Michael O'Riordan November 27, 2017
News Conference News AHA 2017 Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear Todd Neale November 14, 2017
News Conference News AHA 2017 Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI Yael L. Maxwell November 13, 2017
News Daily News Evolocumab ‘Abjectly Fails’ Another Financial Stress Test Michael O'Riordan October 19, 2017
News Daily News Secondary Prevention Lagging Behind in Women With Established Coronary Disease Todd Neale September 22, 2017
News Daily News Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI L.A. McKeown May 23, 2017
News Daily News Long-term MI Risk Among Stable CAD Patients: Some Clues From CORONOR Shelley Wood April 24, 2017
News Conference News ACC 2017 FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo Michael O'Riordan March 17, 2017
News Daily News Meta-analysis Calls Into Question Strength of Guidance for RAS Blockade in Patients With Stable CAD Todd Neale January 19, 2017